The pharmaceutical company Moberg Derma has received a grant of SEK 4,2 million from Vinnova (The Swedish Governmental Agency for Innovation Systems). The grant will be used to develop an innovative patent-protected pharmaceutical product that will further strengthen the company’s position in the area of topical antifungals.

“We are very pleased that we have been awarded this grant which enables a faster development of the project and also for the recognition of our product development concept that it represents. The project will be conducted in co-operation with the Sahlgrenska University Hospital among others”, comments Peter Wolpert, CEO of Moberg Derma. Moberg Derma is developing a portfolio of medical products for skin disorders based on the company’s patented technology as well as acquired projects. This spring the company announced its first commercial agreement and it intends to expand its existing product portfolio through in-house development as well as through further acquisitions.


About Us

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with a direct sales and marketing organization in the U.S. and an extensive distributor network in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Nalox™ in certain ex-U.S. markets) is the leading product for the treatment of nail disorders in the U.S. and Nordic market. The current portfolio will be supplemented by the acquisition and in-licensing of additional products as well as product development with a focus on innovative drug delivery of proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares (OMX: MOB) are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit:



Documents & Links